thomsen-friedenreich antigen and ER-Negative PR-Negative HER2-Negative Breast Cancer

thomsen-friedenreich antigen has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Berger, L; Ditsch, N; Egger, M; Heublein, S; Hofmann, SS; Jeschke, U; Kuhn, C; Mayr, D; Schindlbeck, C; Schuetz, F; Zhu, J	1

Other Studies

1 other study(ies) available for thomsen-friedenreich antigen and ER-Negative PR-Negative HER2-Negative Breast Cancer

Article	Year
Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer. Breast cancer research and treatment, 2020, Volume: 179, Issue:3 Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Biomarkers, Tumor; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Mucin-1; Prognosis; Triple Negative Breast Neoplasms	2020

Article

Year

Evaluation of the anti-Thomsen-Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer.

Breast cancer research and treatment, 2020, Volume: 179, Issue:3

Topics: Antibodies; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antigens, Tumor-Associated, Carbohydrate; Biomarkers, Tumor; Female; Humans; Immunohistochemistry; Lymphatic Metastasis; Middle Aged; Mucin-1; Prognosis; Triple Negative Breast Neoplasms

2020